Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00002412 · ClinicalTrials.gov registry record · Phase 2
A Study of MKC-442 in Combination With Other Anti-HIV Drugs
A Phase 2 study of HIV Infections, sponsored by Triangle Pharmaceuticals.
- Completed
- Registry status
- Phase 2
- Development phase
- 1
- Study location
NCT00002412: Completed Phase 2 study of HIV Infections, sponsored by Triangle Pharmaceuticals.
NCT00002412 is a Phase 2 study of HIV Infections that has completed, run by Triangle Pharmaceuticals. The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00002412, a Phase 2 study of HIV Infections, has completed, sponsored by Triangle Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 1
- Study location
Study Summary
The purpose of this study is to see if it is safe and effective to give MKC-442 plus stavudine (d4T) plus didanosine (ddI) plus hydroxyurea.
Conditions Studied
Interventions
- DRUG Hydroxyurea
- DRUG Stavudine
- DRUG Didanosine
- DRUG Emivirine
Study Locations (1)
Florida
- Dr Robert Wallace - St. Petersburg
Trial Details
| Field | Value |
|---|---|
| Phase | Phase 2 |
What the finished NCT00002412 record still lists
NCT00002412 is an interventional study that assigns participants to a tested intervention. An enrollment target was not published in the registry record, which is common for early-stage or observational entries.
The record links to 1 condition, with HIV Infections appearing as the primary indexed condition, and to 4 interventions - of which Hydroxyurea is the first listed.
NCT00002412 reports a single indexed study location in Florida.
Frequently Asked Questions
What is clinical trial NCT00002412 about?
NCT00002412 is a clinical study titled "A Study of MKC-442 in Combination With Other Anti-HIV Drugs". The purpose of this study is to see if it is safe and effective to give MKC-442 plus stavudine (d4T) plus didanosine (ddI) plus hydroxyurea.
What is the current status of trial NCT00002412?
This trial is currently completed. It is a Phase 2 study.
What conditions does trial NCT00002412 study?
This clinical trial studies the following conditions: HIV Infections.
What interventions are being tested in trial NCT00002412?
The interventions under investigation include: Hydroxyurea (DRUG), Stavudine (DRUG), Didanosine (DRUG), Emivirine (DRUG).
Who is sponsoring clinical trial NCT00002412?
This trial is sponsored by Triangle Pharmaceuticals, which has 3 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00002412 being conducted?
This trial has 1 study location across Florida. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for HIV Infections
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Phase 2b Study Evaluating Oral VH4524184 Regimens in Treatment Naïve Persons With HIV-1 (INNOVATE Study)
RECRUITING · Phase 2
-
Microbiome Metabolites and Alcohol in HIV to Reduce CVD RCT
RECRUITING · Phase 2
-
Cholesterol and Inflammation Lowering Via Bempedoic Acid, an ACL-inhibiting Regimen in HIV Trial (CLEAR HIV Trial)
RECRUITING · Phase 2
-
Imaging Immune Activation in HIV by PET-MR
RECRUITING · Phase 2
-
A Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of a New Formulation of Cabotegravir Long-Acting Administered Intramuscularly in a 4-month Dosing Interval (Q4M)
ACTIVE NOT RECRUITING · Phase 2
-
A Study to Investigate the Virologic Efficacy and Safety of VH3810109 + Cabotegravir Compared to Standard of Care (SOC) in Male and Female Adults Living With Human Immunodeficiency Virus (HIV)
ACTIVE NOT RECRUITING · Phase 2